Literature DB >> 20358262

Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies.

B H Ch Stricker1, T Stijnen.   

Abstract

In pharmaco-epidemiology, the use of drugs is the determinant of interest when studying exposure-outcome associations. The increased availability of computerized information about drug use on an individual basis has greatly facilitated analyses of drug effects on a population-based scale. It seems likely that many negative findings in the early days of pharmaco-epidemiology can be explained by non-differential misclassification because of too simple (yes/no) exposure measures. In this paper, the authors discuss the importance of an adequate definition of drug exposure in pharmaco-epidemiological research and how this time-varying determinant can be analyzed in cohort studies. To reduce the risk of non-differential misclassification, a precise definition of exposure is mandatory and it is important to distinguish the complete follow-up period of a population into mutually exclusive episodes of non-use, past use and current use for each individual. By analyzing exposure to drugs as a time-dependent variable in a Cox regression model, cohort studies with complete coverage of all filled prescriptions can provide us with valid and precise risk estimates of drug-outcome associations. However, such estimates may be biased in the presence of time-dependent confounders which are themselves affected by prior exposure.

Entities:  

Mesh:

Year:  2010        PMID: 20358262      PMCID: PMC2850996          DOI: 10.1007/s10654-010-9451-7

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  12 in total

1.  A survey of childhood malignancies.

Authors:  A STEWART; J WEBB; D HEWITT
Journal:  Br Med J       Date:  1958-06-28

2.  Prenatal x-ray exposure and childhood cancer.

Authors:  B MACMAHON
Journal:  J Natl Cancer Inst       Date:  1962-05       Impact factor: 13.506

Review 3.  Thinking big: large-scale collaborative research in observational epidemiology.

Authors:  Alexander Thompson
Journal:  Eur J Epidemiol       Date:  2009-12-05       Impact factor: 8.082

4.  Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women.

Authors:  A L Herbst; H Ulfelder; D C Poskanzer
Journal:  N Engl J Med       Date:  1971-04-15       Impact factor: 91.245

5.  Alternative data sources in a case-control study of conjugated estrogens and cancer.

Authors:  J E Buring; C J Bain; C H Hennekens
Journal:  Am J Prev Med       Date:  1986 Mar-Apr       Impact factor: 5.043

6.  Reserpine use in relation to breast cancer.

Authors:  O P Heinonen; S Shapiro; L Tuominen; M I Turunen
Journal:  Lancet       Date:  1974-09-21       Impact factor: 79.321

7.  Epidemiology of hepatocellular adenoma. The role of oral contraceptive use.

Authors:  J B Rooks; H W Ory; K G Ishak; L T Strauss; J R Greenspan; A P Hill; C W Tyler
Journal:  JAMA       Date:  1979-08-17       Impact factor: 56.272

8.  Rise in psychotropic drug prescribing in children and adolescents during 1992-2001: a population-based study in the UK.

Authors:  Yingfen Hsia; Karyn Maclennan
Journal:  Eur J Epidemiol       Date:  2009-03-05       Impact factor: 8.082

9.  Thiazide diuretics and the risk for hip fracture.

Authors:  Mariette W C J Schoofs; Marjolein van der Klift; Albert Hofman; Chris E D H de Laet; Ron M C Herings; Theo Stijnen; Huibert A P Pols; Bruno H Ch Stricker
Journal:  Ann Intern Med       Date:  2003-09-16       Impact factor: 25.391

10.  Use of recommended medications after myocardial infarction in Austria.

Authors:  Wolfgang C Winkelmayer; Anna E Bucsics; Alexandra Schautzer; Peter Wieninger; Michaela Pogantsch
Journal:  Eur J Epidemiol       Date:  2007-12-07       Impact factor: 8.082

View more
  48 in total

1.  Medication-related fall incidents in an older, ambulant population: the B-PROOF study.

Authors:  Annelies C Ham; Karin M A Swart; Anke W Enneman; Suzanne C van Dijk; Sadaf Oliai Araghi; Janneke P van Wijngaarden; Nikita L van der Zwaluw; Elske M Brouwer-Brolsma; Rosalie A M Dhonukshe-Rutten; Natasja M van Schoor; Tischa J M van der Cammen; Paul Lips; Lisette C P G M de Groot; André G Uitterlinden; Renger F Witkamp; Bruno H Stricker; Nathalie van der Velde
Journal:  Drugs Aging       Date:  2014-12       Impact factor: 3.923

2.  Influence of the drug exposure definition on the assessment of the antipsychotic metabolic impact in patients initially treated with mood-stabilizers.

Authors:  Marie Tournier; Bernard Bégaud; Audrey Cougnard; Guy-Robert Auleley; Jean Deligne; Claudine Blum-Boisgard; Anne C M Thiébaut; Hélène Verdoux
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

3.  The Rotterdam Study: 2016 objectives and design update.

Authors:  Albert Hofman; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij
Journal:  Eur J Epidemiol       Date:  2015-09-19       Impact factor: 8.082

4.  Digoxin and mortality: lessons for observational studies.

Authors:  Anthonius de Boer; Adam F Cohen
Journal:  Br J Clin Pharmacol       Date:  2015-11-20       Impact factor: 4.335

5.  The Rotterdam Study: 2014 objectives and design update.

Authors:  Albert Hofman; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij
Journal:  Eur J Epidemiol       Date:  2013-11-21       Impact factor: 8.082

6.  Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study.

Authors:  Shu-Yu Tai; Chen-Yu Chien; Yu-Han Chang; Yuan-Han Yang
Journal:  Neurotherapeutics       Date:  2017-07       Impact factor: 7.620

7.  Using Multiple Pharmacovigilance Models Improves the Timeliness of Signal Detection in Simulated Prospective Surveillance.

Authors:  Rolina D van Gaalen; Michal Abrahamowicz; David L Buckeridge
Journal:  Drug Saf       Date:  2017-11       Impact factor: 5.606

8.  Beta-blocker use and fall risk in older individuals: Original results from two studies with meta-analysis.

Authors:  Annelies C Ham; Suzanne C van Dijk; Karin M A Swart; Anke W Enneman; Nikita L van der Zwaluw; Elske M Brouwer-Brolsma; Natasja M van Schoor; M Carola Zillikens; Paul Lips; Lisette C P G M de Groot; Albert Hofman; Renger F Witkamp; André G Uitterlinden; Bruno H Stricker; Nathalie van der Velde
Journal:  Br J Clin Pharmacol       Date:  2017-07-04       Impact factor: 4.335

9.  Immortal time bias in pharmacoepidemiological studies on cancer patient survival: empirical illustration for beta-blocker use in four cancers with different prognosis.

Authors:  Janick Weberpals; Lina Jansen; Myrthe P P van Herk-Sukel; Josephina G Kuiper; Mieke J Aarts; Pauline A J Vissers; Hermann Brenner
Journal:  Eur J Epidemiol       Date:  2017-09-01       Impact factor: 8.082

10.  Associations of statin use with glycaemic traits and incident type 2 diabetes.

Authors:  Fariba Ahmadizar; Carolina Ochoa-Rosales; Marija Glisic; Oscar H Franco; Taulant Muka; Bruno H Stricker
Journal:  Br J Clin Pharmacol       Date:  2019-03-18       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.